Inito, the India-based health-tech company known for pioneering at-home hormone testing, has raised $29 million in Series B funding, marking a significant leap toward its ambition of creating a comprehensive at-home diagnostics platform. The round was led by Bertelsmann India Investments (BII), with strong participation from existing investor Fireside Ventures. This latest infusion brings the company’s total equity funding to $45 million, underscoring growing global confidence in Inito’s technology and vision.
Founded with a mission to simplify healthcare by bringing clinical-grade diagnostics into the home, Inito first gained traction in 2021 with the launch of its fertility monitor. What began as an effort to help women better understand ovulation and hormonal cycles has quickly matured into one of the world’s most trusted at-home fertility systems. Today, Inito has analyzed over 30 million hormone data points, offering users unprecedented insights into biomarkers such as FSH, Estrogen, LH, and PdG — the urine metabolite of Progesterone.
These real-time measurements are interpreted using Inito’s machine-learning models, enabling the platform to decode complex hormone patterns that impact fertility, mood, metabolic health, sleep, and overall well-being. After contributing to tens of thousands of pregnancies globally — a volume comparable to the entire U.S. IVF industry — Inito is now expanding beyond fertility into a wider horizon: a universal at-home diagnostics system powered by AI-engineered antibodies.
A New Era of Diagnostics: AI-Designed Antibodies
At the heart of Inito’s next chapter lies a groundbreaking shift from conventional diagnostics, which rely heavily on traditional antibodies grown inside animals. This legacy approach has long presented limitations: antibodies take months to develop, are expensive to scale, degrade over time, and often lack the sensitivity required for accurate at-home measurements of many biomarkers.
Inito is breaking that bottleneck by leveraging computational protein design and machine-learning models to create synthetic antibodies in silico — without animals, without guesswork, and with far greater precision. These AI-engineered antibodies can be designed to bind more selectively, react more consistently, and remain stable over longer periods, significantly pushing the boundaries of what is possible in home-based testing.
The result is faster innovation, deeper measurement capabilities, and diagnostic tools that meet clinical standards while staying accessible and easy to use.
Co-founders Aayush Rai and Varun AV believe this shift represents a major transformation in how people interact with their health.
“We have always believed that healthcare should start at home,” they said. “Hormones influence nearly everything — fertility, mood, metabolism, energy, sleep — but testing them still depends on slow and infrastructure-heavy systems. If you want to understand your hormones, you shouldn’t have to wait weeks for a lab report. You should be able to do it from home with clinical-grade accuracy. AI-engineered antibodies allow us to build diagnostic tests that simply were not possible before.”
Investors See Global Potential
For Bertelsmann India Investments, Inito’s fusion of deep science and consumer-friendly design represents the future of health diagnostics.
“The future of healthcare lies at the intersection of deep science, AI, and personal wellness — and that’s exactly where Inito is leading,” said Swati Murarka, Principal at BII. “By combining clinical precision with intelligent design, Inito is redefining diagnostics for the modern world. We’re proud to back visionary founders building globally scalable innovation from India — and Inito exemplifies that ambition.”
Long-time supporter Fireside Ventures echoed similar confidence.
“We have seen Inito evolve from a breakthrough idea into a trusted women’s health brand built on deep consumer insight and scientific accuracy,” noted Kannan Sitaram, Co-founder & Partner at Fireside Ventures. “The team’s ability to deliver clinical-grade insights through a simple and accessible solution has earned strong consumer love. We are proud to reaffirm our partnership as they scale their impact globally.”
Expanding Toward a Global, Multi-Test Platform
With this new capital, Inito plans to accelerate its transition from a fertility-focused product to a holistic at-home health diagnostics ecosystem. By enabling diagnostic test development entirely in silico — rather than through slow, inconsistent, animal-based laboratory processes — Inito aims to dramatically expand the number of biomarkers that can be measured accurately at home.
The company envisions a future where individuals anywhere in the world can check key indicators of hormone function, metabolic health, inflammation, nutrition, and chronic disease — all through a single device powered by AI-engineered antibody technology.
Inito’s scaling roadmap includes:
-
Rapid development of new synthetic antibodies for a wide range of biomarkers
-
Expansion of their health insights engine to interpret complex longitudinal data
-
Global regulatory and commercial expansion to make at-home diagnostics universally accessible
-
Integration of next-generation user experience tools to simplify long-term health tracking
Ultimately, Inito aims to give people control of their health data in a way that is deep, continuous, and clinically meaningful — without ever needing to step into a clinic.
A Transformative Step for Consumer Health
By combining machine learning, advanced protein engineering, and user-centric design, Inito is paving the way for a new standard of diagnostic care — one that is personalized, proactive, and accessible to all. With this Series B raise, the company is positioned to shape the next decade of at-home health innovation, bringing clinical-grade testing closer to millions of households worldwide.
